IBEX Technologies Inc logo

IBT - IBEX Technologies Inc Share Price

C$0.22 0.0  0.0%

Last Trade - 24/09/20

Micro Cap
Market Cap £3.20m
Enterprise Value £2.45m
Revenue £2.89m
Position in Universe 1995th / 2683
Unlock IBT Revenue
Relative Strength (%)
1m +26.2%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -24.1%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Jul 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
3.94 3.49 4.11 5.33 4.73 4.31 +1.8%
-52.1 +2,866
Balance Sheet
FINANCIAL BRIEF: : For the nine months ended 30 April 2020, IBEX Technologies Inc revenues increased 20% to C$3.8M. Net income totaled C$662K vs. loss of C$685K. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Research and development expenses decrease of 55% to C$113K (expense), Selling, general and administrative expe decrease of 5% to C$1.4M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


IBT Revenue Unlock IBT Revenue

Net Income

IBT Net Income Unlock IBT Revenue

Normalised EPS

IBT Normalised EPS Unlock IBT Revenue

PE Ratio Range

IBT PE Ratio Range Unlock IBT Revenue

Dividend Yield Range

IBT Dividend Yield Range Unlock IBT Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
IBT EPS Forecasts Unlock IBT Revenue
Profile Summary

IBEX Technologies Inc., through its subsidiaries, IBEX Pharmaceuticals Inc. and BioResearch Products Inc., manufactures and markets enzymes for biomedical use. The Company also manufactures and markets a series of arthritis assays, which enable the study of both the synthesis and degradation of cartilage components. It operates through the production and sale of diagnostic products segment. Its products include IB-C2C-HUSA, C2C Assay, CPII Assay, C1-2C Assay and CS-846 Assay. It provides various individual collagen associated antibodies, such as Ab1320-Rabbit Polyclonal Antibody; Type IX Collagen Antibody, and C1-2C Antibody (Col 2 3/4C short Antibody). Its diagnostic microtiter enzyme-linked immunosorbent assays include C2C-Collagen Type II Cleavage Assay; IB-C2C-HUSA-IBEX C2C Human Urine Sandwich Assay; C1,2C-Collagen Type I and II Cleavage Assay (Col 2 3/4C short antibody); CPII-Procollagen Type II C-Propeptide Assay, and CS846-Aggrecan Chondroitin Sulfate 846 Epitope Assay.

Last Annual July 31st, 2019
Last Interim April 30th, 2020
Incorporated September 2, 1977
Public Since November 14, 1985
No. of Shareholders: n/a
No. of Employees: 15
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange TSX Venture Exchange
Shares in Issue 24,773,244
Free Float (0.0%)
Eligible for
IBT Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for IBT
Upcoming Events for IBT
Frequently Asked Questions for IBEX Technologies Inc
What is the IBEX Technologies Inc share price?

As of 24/09/20, shares in IBEX Technologies Inc are trading at C$0.22, giving the company a market capitalisation of £3.20m. This share price information is delayed by 15 minutes.

How has the IBEX Technologies Inc share price performed this year?

Shares in IBEX Technologies Inc are currently trading at C$0.22 and the price has moved by 0.153k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the IBEX Technologies Inc price has moved by 0.165k% over the past year.

What are the analyst and broker recommendations for IBEX Technologies Inc?

There are no analysts currently covering IBEX Technologies Inc.

When will IBEX Technologies Inc next release its financial results?

IBEX Technologies Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-04-30
What is the IBEX Technologies Inc dividend yield?

IBEX Technologies Inc does not currently pay a dividend.

Does IBEX Technologies Inc pay a dividend?

IBEX Technologies Inc does not currently pay a dividend.

When does IBEX Technologies Inc next pay dividends?

IBEX Technologies Inc does not currently pay a dividend.

How do I buy IBEX Technologies Inc shares?

To buy shares in IBEX Technologies Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of IBEX Technologies Inc?

Shares in IBEX Technologies Inc are currently trading at C$0.22, giving the company a market capitalisation of £3.20m.

Where are IBEX Technologies Inc shares listed? Where are IBEX Technologies Inc shares listed?

Here are the trading details for IBEX Technologies Inc:

Country of listing: Canada
Exchange: CVE
Ticker Symbol: IBT
What kind of share is IBEX Technologies Inc?

Based on an overall assessment of its quality, value and momentum, IBEX Technologies Inc is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a IBEX Technologies Inc share price forecast 2020?

We were not able to load any forecast data for IBEX Technologies Inc.

How can I tell whether the IBEX Technologies Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like IBEX Technologies Inc. Over the past six months, the relative strength of its shares against the market has been 71.01%. At the current price of C$0.22, shares in IBEX Technologies Inc are trading at 34.29% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the IBEX Technologies Inc PE Ratio?

The IBEX Technologies Inc PE ratio based on its reported earnings over the past 12 months is 20.22. The shares are currently trading at C$0.22.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of IBEX Technologies Inc?

IBEX Technologies Inc's management team is headed by:

Paul Baehr - CHM
Thomas Hecht - IND
Robert DeLuccia - LED
Danilo Netto - IND
Richard Collin - FID
Joseph Zimmermann - DRC
Bruce Connop - DRC
Who are the major shareholders of IBEX Technologies Inc?

Here are the top five shareholders of IBEX Technologies Inc based on the size of their shareholding:

MILFAM LLC Corporation
Percentage owned: 16.47% (4.08m shares)
Baehr (Paul) Individual Investor
Percentage owned: 9.92% (2.46m shares)
DeLuccia (Robert J) Individual Investor
Percentage owned: 0.27% (68.0k shares)
Netto (Danilo) Individual Investor
Percentage owned: 0.09% (21.5k shares)
Miller (Lloyd Ivan III) Individual Investor
Percentage owned: % (n/a shares)
Similar to IBT
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.